Jubilant Therapeutics Inc., a US-based biopharmaceutical company, announced on Friday that it has completed a pre-Investigational New Drug (IND) meetings with the US Food and Drug Administration (FDA) regarding the development plan, clinical trial design, and dosing strategy for the Phase I / II trial of JB1-802, a dual inhibitor of LSD1 and HDAC6, for the treatment of small cell lung cancer (SCLC), treatment-induced neuroendocrine prostate cancer, and other mutation-defined neuroendocrine tumours.
A pre-IND meeting provides the firm with an opportunity to openly communicate with the US FDA, discuss the development plan for the IND, and receive advice from the agency on the new drug candidate's planned clinical trial.
The FDA responded to the company's questions, offered guidance, and approved the proposed development plan for the product, after reviewing the pre-clinical data submitted, the plans to generate additional data, and the protocol of the Phase I / II clinical trial.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review